Your browser doesn't support javascript.
loading
An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.
Leon, Giovanny; Carbonel, Christophe; Rampuria, Aparajit; Rajpoot, Ravindra Singh; Joshi, Parth; Kanavos, Panos.
Affiliation
  • Leon G; Price Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
  • Carbonel C; Price Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
  • Rampuria A; Price Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
  • Rajpoot RS; Value and Access, Novartis Healthcare Private Limited, Hyderabad, India.
  • Joshi P; Value and Access, Novartis Healthcare Private Limited, Hyderabad, India.
  • Kanavos P; Department of Health Policy and Medical Technology Research Group-LSE Health, The London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. p.g.kanavos@lse.ac.uk.
Eur J Health Econ ; 2024 Sep 19.
Article in En | MEDLINE | ID: mdl-39299943
ABSTRACT
This paper analyses the structure of and variability in taxation and prescription drug distribution policies and quantifies the impact of such policies on the cost of prescription drugs to health systems in 35 countries. Taxes on prescription drugs remain highly prevalent (83% of the sample) although 63% of the sample countries implement a lower than standard VAT rate. Three remuneration types of the wholesale and retail distribution chain have been identified. Wholesale and retail distributors are remunerated on a regressive mark-up basis, which is price-dependent, although fixed fees and fixed percentages, which are non-price dependent, are also highly prevalent. Price component analysis for three groups of products classed as high-, medium- and low-priced suggests that mark-ups plus taxes varied significantly across countries and products, and ranged from 5% to 187% of ex-factory prices. Average margins also vary significantly by countries and products ranging 5-65% of retail prices. The cost of distribution and taxation contributes significantly to prescription drug costs for health systems. Although distribution chain remuneration raises efficiency and overall affordability questions, these need to be considered together with the regulatory framework shaping market structure of the distribution chain, as well as any prevailing horizontal and vertical integration policies. The overall cost of prescription drugs could be reduced immediately by eliminating taxation; this could go some way to alleviate fiscal pressures on health budgets, whilst avoiding resource re-allocation from health to other sectors.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Health Econ / Eur. j. health econ / European journal of health economics Journal subject: SAUDE PUBLICA / SERVICOS DE SAUDE Year: 2024 Document type: Article Affiliation country: Switzerland Country of publication: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Health Econ / Eur. j. health econ / European journal of health economics Journal subject: SAUDE PUBLICA / SERVICOS DE SAUDE Year: 2024 Document type: Article Affiliation country: Switzerland Country of publication: Germany